- Report
- April 2025
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- June 2025
- 287 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- March 2025
- 210 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- January 2024
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- October 2021
- 100 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- September 2021
- 100 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- February 2024
- 125 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- January 2022
- 122 Pages
Global
From €4255EUR$4,750USD£3,627GBP
- Report
- March 2022
- 180 Pages
Global
From €3224EUR$3,600USD£2,749GBP
- Report
- May 2024
- 292 Pages
Global
From €4474EUR$4,995USD£3,814GBP
- Report
- October 2023
- 113 Pages
Global
From €3500EUR$4,186USD£3,088GBP
- Report
- June 2025
- 50 Pages
Global
From €2374EUR$2,650USD£2,023GBP
- Report
- June 2025
- 50 Pages
Global
From €2374EUR$2,650USD£2,023GBP

Pethidine, also known as meperidine, is an opioid analgesic used to treat moderate to severe pain. It is a synthetic opioid, meaning it is not derived from the opium poppy plant. Pethidine is typically administered intravenously or intramuscularly, and is often used in combination with other analgesics. It is commonly used in the treatment of postoperative pain, labor pain, and cancer pain.
Pethidine is a controlled substance in many countries, and is subject to strict regulations. It is also subject to abuse and misuse, and can cause serious side effects such as respiratory depression, nausea, and vomiting. As a result, it is not recommended for long-term use.
The pethidine market is a subset of the larger analgesics market. It is a highly competitive market, with many companies offering pethidine-based products. Some of the major players in the market include Pfizer, Sanofi, GlaxoSmithKline, Merck, and Novartis. Show Less Read more